TrialJournal of neuro-oncology2020

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

Martin van den Bent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.